Anyone who has been having injectable treatment in west London for a decade will have noticed that the appointment has changed shape. There is more talking and less product. Plans run across months rather than across a single visit. Practitioners are more willing to decline. And the phrase patients now hear most often is not what can be added but what should be left alone.
This is not a west London eccentricity. It reflects a broader change in how injectables are practised, and it has arrived faster in districts like Chiswick because the market there is built on repeat local custom, where a result that ages badly is a reputational problem the practitioner cannot escape.
Lower doses and longer intervals
The first visible change is dosing. Botulinum toxin practice has moved towards using less, aiming at softening rather than abolishing movement, and towards treating patterns of muscle activity rather than treating a list of areas. In practical terms that means a treatment that leaves the brow mobile, retains expression and often uses fewer units than the same patient would have received several years ago.
Intervals have lengthened alongside it. Where a three-month cycle was once treated as standard, many west London practitioners now work with patients on longer intervals, treating when movement returns rather than when the calendar says so. Some patients find that after several years of consistent treatment the interval naturally extends. Repeat treatment sooner than twelve weeks is not usually recommended, and a clinic that wants to see you every eight is working to a commercial rhythm.
The driver is partly aesthetic taste and partly clinical. A completely immobile upper face reads as treated, and patients in this part of London have been clear for some time that this is not what they are buying.
From volume to structure to skin quality
The second and larger change is in how filler is used. Three phases are visible in the London market over the last fifteen years. The first was line filling. The second was volumising, with product placed to replace lost facial volume, which at its worst produced the overfilled appearance that made a generation of patients cautious. The third, current phase is more conservative and more anatomical: small volumes placed to support structure, combined with treatments aimed at the quality of the skin itself.
Practically, that shows up as a shift in what west London clinics sell. Skin boosters, polynucleotides and biostimulatory injectables have grown as a share of appointments, while single-visit multi-syringe filler plans have declined. Practitioners increasingly treat the skin envelope as the primary target and reserve structural filler for cases where the assessment genuinely shows a structural deficit.
The most experienced injectors in west London are now defined by what they decline to do, not by what they offer.
Assessment has become the differentiator
The third change is the most consequential and the least visible to patients. Assessment has become more rigorous.
- Filler history matters. Hyaluronic acid products can persist far longer than early marketing suggested, and a patient who believes their filler from four years ago has gone may still be carrying product. Treating on that assumption produces distortion that neither patient nor practitioner expects.
- Ultrasound has entered practice. A growing number of London practitioners use ultrasound to map previously placed product and to assess vascular anatomy before injecting. It is not universal and it is more common centrally than in the outer districts, but its use is rising and it is a reasonable thing to ask about if you have had multiple previous treatments.
- Declining is normal. The willingness to say that a patient has enough product, or that the concern raised is not an injectable problem, has become a mark of quality rather than a lost sale.
The regulatory backdrop
Two aspects of the framework shape what clinics can do. Botulinum toxin is a prescription-only medicine, which means an appropriate prescriber must assess the patient in person and prescribe for that patient specifically. Remote prescribing for cosmetic injectables is not considered acceptable in professional guidance. Advertising rules also restrict how prescription-only medicines may be promoted to the public, which is why compliant clinics discuss areas and outcomes rather than brand names.
Dermal fillers, by contrast, are regulated as devices, and for adults there is no legal restriction on who may inject them. It is a criminal offence in England to administer either botulinum toxin or filler for cosmetic purposes to a person under eighteen other than under a doctor's direction. That asymmetry between the two product categories is the single most important thing for a patient to understand, and it is why practitioner registration does the work that the law does not.
What it costs in west London now
| Treatment | Indicative range | Direction |
|---|---|---|
| Botulinum toxin, one area | £180 to £320 | Stable, fewer units used |
| Botulinum toxin, three areas | £300 to £520 | Stable |
| Dermal filler, per millilitre | £350 to £700 | Fewer millilitres per plan |
| Skin booster or polynucleotide course | £750 to £1,350 for three | Rising share of appointments |
| Biostimulatory injectable | £400 to £700 | Rising |
The interesting number is not the unit price but the plan total. Patients spending the same annually as five years ago are now buying a different mix: less filler, more skin quality work, more review appointments and more assessment. That is a better use of the same money, provided the assessment is real.
What this looks like in practice
In a well-run west London practice the pattern is consistent. The first appointment is longer than the treatment appointment. The plan is written down and staged across months. Photography is standardised so that the result can actually be judged. Review is booked at two weeks for toxin and at eight to twelve weeks for anything biostimulatory. And the practitioner tells you at the outset what they will not do.
Practitioner-led clinics in the area, including Dr Harry Clinic, work in this staged, assessment-first way rather than delivering a full plan in a single visit, which is the pattern that has come to define the district. It is slower, it produces fewer dramatic photographs, and it is the reason west London patients tend to stay with one practitioner for years.
What patients should take from it
- If a clinic wants to deliver everything in one appointment, ask why. Staging exists for clinical reasons, not scheduling ones.
- If you have had filler before, say so in detail, and expect to be asked. Product from years ago is a live consideration, not history.
- If you are told you do not need something, take it seriously. That is the most valuable sentence in the consultation.
- Judge results at the right time. Two weeks for toxin, eight to twelve weeks for biostimulation, three months for skin quality work.
- Verify the practitioner on the public registers before you attend, not after something goes wrong.
The direction of travel in west London is towards less product, more thought and longer relationships. For patients, that is an improvement, and it is worth choosing a clinic that has already made the shift rather than one still selling by the syringe.